It seems we all know someone who has been adversely affected by Cancer. As of 2015 cancer is one of the leading causes of death right behind heart disease. There are a reported 14 million new cases of cancer reported each year worldwide, while it claims the lives of over 8 million a year. It’s expected there will be an average of 22 million new cases diagnosed every year within the next 2 decades. Diabetes is another huge issue. It is a worldwide epidemic with so far no cure. 387 million people around the world live with diabetes. In the U.S. alone, there’s an estimated 29 million people that have diabetes with over 1.7 million diagnosed each year. It’s currently the seventh leading cause of death worldwide.
Finding treatments is what PharmaCyte Biotech is tackling head on. PharmaCyte Biotech is a clinical stage biotechnology company that focuses on developing treatments for both cancer and diabetes based on a revolutionary live-cell encapsulation technology known as Cell In A Box.
Cell in a Box encapsulates genetically modified cells to do two things. For Cancer, the cells convert a chemotherapy drug into its cancer-killing form. For Diabetes, it encapsulates genetically modified cells that produce insulin when a patient’s pancreas isn’t working properly. Just one of these roller bottles contains hundreds of tiny beads or capsules filled with live, growing cells. Each of these capsules is known as “Cell In A Box.”
The highly technical procedure starts with 100 cells placed into a tiny capsule. These capsules are then placed inside of a bioreactor or a roller bottle. The porous capsules then spend about 2 weeks living in a “nutrient bath.” The tiny pores on the outside of the capsules allow small molecules to wash in to the capsule carrying food and nutrients to the cells and allow waste products from the cells to leave. This type of environment helps the cells grow from 100 to 10,000 cells per capsule. They are then packaged and ready for clinical trials. The first trial is used for the treatment of advanced inoperable pancreatic cancer. PharmaCyte Biotech combines Cell In A Box with one-third the normal dose of the chemotherapy drug ifosfamide.
The encapsulated cells convert the chemo drug to its cancer-killing form. The tiny capsules are placed as close to the tumor as possible to deliver the highest concentration of the cancer-killing drug at the source of the cancer. Not only is this “targeted chemotherapy” more effective, but it also eliminates the normal side effects from chemotherapy because of the small dose.
In addition to treating pancreatic cancer, PharmaCyte will use this same treatment to improve the quality of life in patients with pancreatic cancer and other abdominal cancers. This will include ascites, a malignant fluid that accumulates in the abdomen, and the unbearable pain. Both are directly related to the growth of these abdominal tumors. This same technology has been found to be very effective in the treatment of diabetes by encapsulating cells which trigger the production of insulin. The cells that will be encapsulated in PharmaCyte Biotech’s technology have shown in preclinical studies that they can end diabetes. By encapsulating those cells in Cell in a Box, PharmaCyte may be able to create an artificial pancreas. 20 years in the making Cell In A Box now has its goal in sight.
If you are interested in finding out more visit PharmaCyte.com.